Delcath Systems, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $20.6 million for the three months ended September 30, 2025, compared to $11.2 million in the same period last year. For the nine months ending September 30, 2025, revenues surged to $64.5 million, up from $22.1 million in the prior year. The increase in revenue is attributed to the expanding commercial demand for the HEPZATO KIT in the United States and CHEMOSAT in Europe, with 22 facilities treating patients with HEPZATO compared to 11 in the previous year. The gross profit for the quarter was $17.9 million, resulting in a gross margin of approximately 87%, while the company reported a net income of $830,000 for the quarter, a notable improvement from a loss of $1.3 million in the same quarter of 2024.
Delcath's operational expenses also increased, with total operating expenses for the third quarter amounting to $18.3 million, up from $10.8 million in the prior year. This rise was primarily driven by higher research and development costs, which reached $8 million, reflecting the company's investment in expanding its clinical team and initiating new clinical trials. Selling, general, and administrative expenses also rose to $10.3 million, reflecting ongoing commercial expansion efforts. Despite these increased costs, the company achieved an operating income of $2.8 million for the nine-month period, a significant turnaround from an operating loss of $15.4 million in the same timeframe last year.
In terms of strategic developments, Delcath's lead product, the HEPZATO KIT, received FDA approval in August 2023 and began commercial use in January 2024. The company is actively pursuing clinical trials to evaluate HEPZATO's efficacy in treating liver-dominant metastatic colorectal cancer and metastatic breast cancer, with patient enrollment expected to begin in early 2026. Additionally, the company has secured six orphan drug designations from the FDA for various cancer treatments, indicating a strong commitment to addressing unmet medical needs in oncology.
Delcath's balance sheet reflects a robust liquidity position, with cash and cash equivalents totaling $41.8 million and short-term investments of $47.1 million as of September 30, 2025. This is a significant increase from $8.3 million in cash and $5.7 million in investments a year earlier. The company believes its current cash resources will support operations for at least the next 12 months, bolstered by net cash provided by operating activities of $14.3 million during the nine months ended September 30, 2025. The company is also focused on managing supply chain risks and has sufficient inventory to meet anticipated demand for its products.
Looking ahead, Delcath remains optimistic about its growth trajectory, driven by the anticipated success of its clinical trials and the ongoing commercialization of HEPZATO and CHEMOSAT. The company is committed to expanding its market presence and enhancing product adoption rates, with plans to leverage its recent clinical data to support reimbursement efforts in various jurisdictions. However, Delcath acknowledges the inherent risks associated with the biopharmaceutical industry, including regulatory challenges and market competition, which could impact its future performance.
About DELCATH SYSTEMS, INC.
Delcath Systems, Inc. develops interventional oncology products targeting primary and metastatic liver cancers. Its core offerings include the HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy delivery. The company serves patients with liver metastases from cancers such as uveal melanoma, colorectal, breast, and neuroendocrine tumors. It focuses on clinical development, regulatory approval, and commercialization of innovative treatments to address significant unmet medical needs in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.